Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Technical Know How
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3499
Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.
Synuclein proteins are a family of charged proteins found throughout the body. One protein from this family, alpha-synuclein, is found extensively in neurons and is a major component of pathological inclusions that characterize several neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, neurodegeneration with brain iron accumulation type 1, and multiple system atrophy, which collectively are termed synucleinopathies.
IPSCIO Record ID: 224822
IPSCIO Record ID: 26360
The Licensor will retain certain rights to conduct development of the Licensed Products and an option to co-promote PRX002.
Thereafter, during the term of the License Agreement, the Licensor and the Licensee will work exclusively with each other to research and develop antibody products targeting alpha-synuclein.
A tiered, high single-digit to high double-digit royalties in the teens on ex-U.S. annual net sales, subject to certain adjustments. In the United States, the parties will share all development and commercialization.
The rights granted apply to the healthcare industry.